Medical Uses
Mayzent (siponimod) is a sphingosine 1-phosphate (S1P) receptor modulator used for the treatment of adult patients with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Mayzent (siponimod) is a sphingosine 1-phosphate (S1P) receptor modulator used for the treatment of adult patients with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Recommended Dosage: The recommended maintenance dosage of Siponimod is 2 mg taken orally. The recommended maintenance dosage in patients with a CYP2C9*1/*3 or *2/*3 genotype is 1 mg. Tablets should be taken whole; do not split, crush, or chew. Assessments are needed before initiating this oral therapy.
First-dose monitoring is required for patients with sinus bradycardia, first- or second-degree [Mobitz type I] atrioventricular (AV) block, or a known history of myocardial infarction or heart failure.